Citations

Clear

861 citation(s) found for "Sd, Wexner".

Home- vs Office-Based Narrowband UV-B Phototherapy for Patients With Psoriasis
Armstrong, April W. , Lim, Henry W., Johnson, Sandra Marchese , Claiborne, W. C. Cole, Kalb, Robert E. , Jakus, Jeannette , Mangold, Aaron R. , Bagel, Jerry , Fretzin, Scott , Sheehan, Michael P. , Krell, James, Reeder, Margo J. , Kartono, Francisca, Bridges, Alisha, Nehal, Umbereen S., Schaecher, Kenneth L., Howard, Leah, Eakin, Guy S. , Báez, Suzette , Bishop, Brooke E., Fitzsimmons, Robert C., Papadopoulos, Maryte , Song, William B. , Linn, Kristin A. , Duffin, Kristina Callis , Mangold, A R , Gelfand, Joel M. , Lim, Henry W. , Feldman, Steven R. , Flowers, Richard Hal , Bhutani, Tina , Durkin, John R. , Kaffenberger, Jessica A. , Takeshita, Junko , Fielding, Eric Jameson , Bishop, B., Fitzsimmons, Robert C. , Hubbard, Rebecca A. , Shin, Daniel B.

Mayo Clinic

JAMA Dermatology | September 25, 2024 | Volume: 160 | Issue: 12 | Pages: 1320

10.1001/jamadermatol.2024.3897 | PMID 39319513 Get It

Importance Office-based phototherapy is cost-effective for psoriasis but difficult to access. Home-based phototherapy is patient preferred but has limited clinical data, particularly in patients with darker skin. Objective To compare the effectiveness of home- vs office-based narrowband UV-B phototherapy for psoriasis. Design, Setting, and Participants The Light Treatment Effectiveness study was an investigator-initiated, pragmatic, open-label, parallel-group, multicenter, noninferiority randomized clinical trial embedded in routine care at 42 academic and private clinical dermatology practices in the US. Enrollment occurred from March 1, 2019, to December 4, 2023, with follow-up through June 2024. Participants were 12 years and older with plaque or guttate psoriasis who were candidates for home- and office-based phototherapy. Interventions Participants were randomized to receive a home narrowband UV-B machine with guided mode dosimetry or routine care with office-based narrowband UV-B for 12 weeks, followed by an additional 12-week observation period. Main Outcomes and Measures The coprimary effectiveness outcomes were Physician Global Assessment (PGA) dichotomized as clear/almost clear skin (score of ≤1) at the end of the intervention period and Dermatology Life Quality Index (DLQI) score of 5 or lower (no to small effect on quality of life) at week 12. Results Of 783 patients enrolled (mean [SD] age, 48.0 [15.5] years; 376 [48.0%] male), 393 received home-based phototherapy and 390 received office-based phototherapy, with 350 (44.7%) having skin phototype (SPT) I/II, 350 (44.7%) having SPT III/IV, and 83 (10.6%) having SPT V/VI. A total of 93 patients (11.9%) were receiving systemic treatment. At baseline, mean (SD) PGA was 2.7 (0.8) and DLQI was 12.2 (7.2). At week 12, 129 patients (32.8%) receiving home-based phototherapy and 100 patients (25.6%) receiving office-based phototherapy achieved clear/almost clear skin, and 206 (52.4%) and 131 (33.6%) achieved DLQI of 5 or lower, respectively. Home-based phototherapy was noninferior to office-based phototherapy for PGA and DLQI in the overall population and across all SPTs. Home-based phototherapy, compared to office-based phototherapy, was associated with better treatment adherence (202 patients [51.4%] vs 62 patients [15.9%]; P < .001), lower burden of indirect costs to patients, and more episodes of persistent erythema (466 of 7957 treatments [5.9%] vs 46 of 3934 treatments [1.2%]; P < .001). Both treatments were well tolerated with no discontinuations due to adverse events. Conclusions and Relevance In this randomized clinical trial, home-based phototherapy was as effective as office-based phototherapy for plaque or guttate psoriasis in everyday clinical practice and had less burden to patients. Trial Registration ClinicalTrials.gov Identifier: NCT03726489
Association of Serum Endocannabinoid Levels with Pancreatitis and Pancreatitis-Related Pain
Goodman, Marc T. , Lombardi, Christina , Torrens, Alexa , Saloman, Jami L. , Yang, Yunlong, Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E. , Conwell, Darwin L. , Hart, Phil A. , Park, Walter G. , Topazian, Mark, Vege, Santhi Swaroop , Andersen, Dana K. , Yadav, Dhiraj , Goodman, Marc T , Vege, Santhi S, Saloman, Jami L , Bresee, Catherine J. , Li, Liang , Forsmark, Chris E. , Conwell, Darwin L. , Van Den Eeden, Stephen K , Bellin, Melena D. , Serrano, José , Pandol, Stephen J. , Piomelli, Daniele

Mayo Clinic

Cannabis & Cannabinoid Research | September 18, 2024 | Volume: 10 | Issue: 1 | Pages: 60-70

10.1089/can.2024.0079 | PMID 39291350 Get It

Background and Aims: This investigation examined the association of pancreatitis and pancreatitis-related pain with serum levels of two endocannabinoid molecules such as anandamide (AEA) and 2-arachidonoylglycerol (2-AG) and two paracannabinoid molecules such as oleoylethanolamide (OEA) and palmitoylethanolamide (PEA). Methods: A case–control study was conducted within the Prospective Evaluation of Chronic Pancreatitis for Epidemiological and Translational Studies, including participants with no pancreas disease ( N = 56), chronic abdominal pain of suspected pancreatic origin or indeterminate chronic pancreatitis (CP) ( N = 22), acute pancreatitis ( N = 33), recurrent acute pancreatitis ( N = 57), and definite CP ( N = 63). Results: Circulating AEA concentrations were higher in women than in men ( p = 0.0499), and PEA concentrations were higher in obese participants than those who were underweight/normal or overweight ( p = 0.003). Asymptomatic controls with no pancreatic disease had significantly ( p = 0.03) lower concentrations of AEA compared with all disease groups combined. The highest concentrations of AEA were observed in participants with acute pancreatitis, followed by those with recurrent acute pancreatitis, chronic abdominal pain/indeterminant CP, and definite CP. Participants with pancreatitis reporting abdominal pain in the past year had significantly ( p = 0.04) higher concentrations of AEA compared with asymptomatic controls. Levels of 2-AG were significantly lower ( p = 0.02) among participants reporting abdominal pain in the past week, and pain intensity was inversely associated with concentrations of 2-AG and OEA. Conclusions: Endocannabinoid levels may be associated with stage of pancreatitis, perhaps through activation of the CB1 receptor. Validation of our findings would support the investigation of novel therapeutics, including cannabinoid receptor-1 antagonists, in this patient population.
A pleiotropic recurrent dominant ITPR3 variant causes a complex multisystemic disease
Molitor, Anne , Lederle, Alexandre , Radosavljevic, Mirjana , Sapuru, Vinay , Thomas, Megan E. Zavorka, Yang, Jianying , Shirin, Mahsa , Collin-Bund, Virginie , Jeřábková, Kateřina , Miao, Zhichao , Bernard, Alice , Grenot, Pierre , Lewis, Elyssa G., Person, Richard, Esperón-Moldes, Uxía-Saraiva, Kaare, Milja, Nokelainen, Pekka, Batzir, Nurit Assia , Hoffer, Gal Zaks, Stemmelen, Tristan , Naegely, Lydie , Hanauer, Antoine , Bibi‐Triki, Sabrina , Grün, Sarah, Jung, Sophie , Busnelli, Ignacio, Tripolszki, Kornélia , Ordoñez, Natalia, Song, Eunkyung , Zajo, Kristin , Partida‐Sánchez, Santiago , Robledo‐Avila, Frank , Kumánovics, Attila , Pichot, Angélique , Toker, Ori , Mejía, César , Parvaneh, Nima , Knapp, Esther , Hersh, Joseph H., Kenney, Heather , Bajwa, Rajinder , Thomas, Caroline , Ehl, Stephan , Isidor, Bertrand , Abraham, Roshini S. , Hite, Richard K. , Bertoli‐Avella, Aida M. , Bahram, Seiamak , Zavorka Thomas, Megan E , Jerabkova-Roda, Katerina , Rolli, Véronique , Grenot, Pierre , Castro, Carla Noemi , Rosenzwajg, Michelle , Person, Richard , Batzir, Nurit Assia , Hoffer, Gal Zaks , Paul, Nicodème , Stemmelen, Tristan , Naegely, Lydie , Hanauer, Antoine , Bibi-Triki, Sabrina , Jung, Sophie , Bauer, Peter , Zajo, Kristin , Partida-Sanchez, Santiago , Robledo-Avila, Frank , Kumanovics, Attila , Louzoun, Yoram , Hirschler, Aurélie , Pichot, Angélique , Toker, Ori , Mejía, Cesar Andrés Muñoz , Parvaneh, Nima , Knapp, Esther , Delmonte, Ottavia M , Notarangelo, Luigi D , Goetz, Jacky G , Kahwash, Samir B , Carapito, Christine , Bajwa, Rajinder P S , Thomas, Caroline , Ehl, Stephan , Isidor, Bertrand , Carapito, Raphael , Abraham, Roshini S , Hite, Richard K , Bahram, Seiamak , Esperón-Moldes, Uxia , Al‐Ali, Ruslan , Kenney, Heather , Kahwash, Samir B. , Marcus, Nufar

Mayo Clinic

Science Advances | September 13, 2024 | Volume: 10 | Issue: 37 | Pages: No page available

10.1126/sciadv.ado5545 | PMID 39270020 Get It

Inositol 1,4,5-trisphosphate (IP3) receptor type 1 ( ITPR1 ), 2 ( ITPR2 ), and 3 ( ITPR3 ) encode the IP3 receptor (IP3R), a key player in intracellular calcium release. In four unrelated patients, we report that an identical ITPR3 de novo variant—NM_002224.3:c.7570C>T, p.Arg2524Cys—causes, through a dominant-negative effect, a complex multisystemic disorder with immunodeficiency. This leads to defective calcium homeostasis, mitochondrial malfunction, CD4 + lymphopenia, a quasi-absence of naïve CD4 + and CD8 + cells, an increase in memory cells, and a distinct TCR repertoire. The calcium defect was recapitulated in Jurkat knock-in. Site-directed mutagenesis displayed the exquisite sensitivity of Arg 2524 to any amino acid change. Despite the fact that all patients had severe immunodeficiency, they also displayed variable multisystemic involvements, including ectodermal dysplasia, Charcot-Marie-Tooth disease, short stature, and bone marrow failure. In conclusion, unlike previously reported ITPR1-3 deficiencies leading to narrow, mainly neurological phenotypes, a recurrent dominant ITPR3 variant leads to a multisystemic disease, defining a unique role for IP3R3 in the tetrameric IP3R complex.
NCCN Guidelines® Insights: Colorectal Cancer Screening, Version 1.2024
Llor, Xavier , Abbass, Mohammad Ali , Chen, Christopher T. , Cooper, Gregory S. , Early, Dayna S., Friedman, Mark , Fudman, David , Giardiello, Francis M., Glaser, Kathryn , Gurudu, S, Hall, Michael J. , Issaka, Rachel B. , Kidambi, Trilokesh D. , Lazenby, Audrey J., Maratt, Jennifer K. , Markowitz, Arnold J. , Marsano, Joseph, Olortegui, Kinga Skowron , Peter, Shajan , Porter, Laura , Shafi, Mehnaz, Terdiman, Jonathan P., Vu, Peter , Wood, Elizabeth H., Cassara, Carly J., Gurudu, Surya, Ness, Reid M. , Bishu, Shrinivas , Huang, Lyen C. , Katona, Bryson W , May, Folasade P. , Mayer, Robert J. , Olortegui, Kinga S. , Patel, Swati , Stanich, Peter P. , Weiss, Jennifer M. , Wood, Elizabeth, Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 5, 2024 | Volume: 22 | Issue: 7 | Pages: 438-446

10.6004/jnccn.2024.0047 | PMID 39236750 Get It

The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. These NCCN Guidelines Insights focus on select recent updates to the NCCN Guidelines, including a section on primary and secondary CRC prevention, and provide context for the panel’s recommendations regarding the age at which to initiate screening in average-risk individuals and those with increased risk based on personal history of childhood, adolescent, and young adult cancer.
Multiparametric MRI Scoring System of the Pancreas for the Diagnosis of Chronic Pancreatitis
Tirkes, Temel , Yadav, Dhiraj , Conwell, Darwin L. , Zhao, Xuandong, Dasyam, Anil K. , Halappa, Vivek Gowdra, Patel, Aashish, Shah, Zarine K. , Swensson, Jordan , Takahashi, Naoki , Wachsman, Ashley, Yang, Yunlong, Hart, Phil A. , Park, Walter G. , Vege, Santhi Swaroop , Topazian, Mark , Territo, Paul R. , Persohn, Scott A., Andersen, Dana K. , Fogel, Evan L. , Venkatesh, Sudhakar K , Takahashi, Naoki , Dasyam, Anil K , Venkatesh, Sudhakar K. , Li, Liang , Jennings, Kristofer , Pandol, Stephen J.

Mayo Clinic

Journal of Magnetic Resonance Imaging | September 3, 2024 | Volume: 61 | Issue: 5 | Pages: 2183-2194

10.1002/jmri.29594 | PMID 39225586 Get It

BackgroundDuctal features alone may not offer high diagnostic sensitivity or most accurate disease severity of chronic pancreatitis (CP).PurposeDiagnose CP based on multiparametric MRI and MRCP features.Study TypeProspective.PopulationBetween February 2019 and May 2021, 46 control (23 males, 49.3 ± 14.1 years), 45 suspected (20 males, 48.7 ± 12.5 years), and 46 definite (20 males, 53.7 ± 14.6 years) CP patients were enrolled at seven hospitals enrolled in the MINIMAP study. CP classification was based on imaging findings and clinical presentation.Field Strength and Sequences1.5 T. T1‐weighted (T1W) spoiled gradient echo, T1 map with variable flip angle, dual‐echo Dixon, secretin‐enhanced MRCP before and after secretin infusion.AssessmentDual‐echo fat fraction (FF), T1 relaxation time, extracellular volume (ECV), T1 signal intensity ratio of the pancreas to the spleen (T1 score), arterial‐to‐venous enhancement ratio (AVR), pancreatic tail diameter (PTD), pancreas volume, late gadolinium enhancement, pancreatic ductal elasticity (PDE), and duodenal filling grade of secretin‐enhanced MRCP were measured.Statistical TestsLogistic regression analysis generated CP‐MRI and secretin‐enhanced CP‐SMRI scores. Receiver operating characteristics analysis was used to differentiate definite CP from control. Interobserver agreement was assessed using Lin's concordance correlation coefficient.ResultsCompared to control, definite CP cohort showed significantly higher dual‐echo FF (7% vs. 11%), lower AVR (1.35 vs. 0.85), smaller PTD (2.5 cm vs. 1.95 cm), higher ECV (28% vs. 38%), and higher incidence of PDE loss (6.5% vs. 50%). With the cut‐off of >2.5 CP‐MRI score (dual‐echo FF, AVR, and PTD) and CP‐SMRI score (dual‐echo FF, AVR, PTD, and PDE) had cross‐validated area under the curves of 0.84 (sensitivity 87%, specificity 68%) and 0.86 (sensitivity 89%, specificity 67%), respectively. Interobserver agreement for both CP‐MRI and CP‐SMRI scores was 0.74.ConclusionThe CP‐MRI and CP‐SMRI scores yielded acceptable performance and interobserver agreement for the diagnosis of CP.Evidence Level1Technical EfficacyStage 2
Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials
Fakhri, Bita , Wang, Victoria , Perez‐Burbano, Gabriela, Wall, Anna, Mandrekar, Sumithra J. , Parikh, Sameer A. , Woyach, Jennifer A. , Shanafelt, Tait D. , Woyach, Jennifer A , Parikh, Sameer A , Shanafelt, Tait D , Fakhri, Bita

Mayo Clinic

British Journal of Haematology | September 2, 2024 | Volume: 205 | Issue: 4 | Pages: 1645-1648

10.1111/bjh.19710 | PMID 39219152 Get It

Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Huang, Ying , Cashen, Amanda F. , Vaughn, John L, Badar, Talha , Sethi, Tarsheen , Reddy, Nishitha , Bello, Celeste, Kothari, Shalin , Hernandez‐Ilizaliturri, Francisco J. , Svoboda, Jakub , Glenn, Martha, Cohen, Jonathon B. , Sorge, Caryn, Christian, Beth , Herrera, Alex F. , Vaughn, John L. , Epperla, Narendranath , Badar, Talha , Karmali, Reem , Cohen, Jonathon B , Herrera, Alex F , Hamadani, Mehdi , Costa, Luciano J , Xavier, Ana C , Epperla, Narendranath , Hanel, Walter G. , Barta, Stefan K , Caimi, Paolo F. , Karmali, Reem , Chavez, Julio C , Lansigan, Frederick , Hamadani, Mehdi , Costa, Luciano J.

Mayo Clinic

Blood Advances | August 30, 2024 | Volume: 8 | Issue: 21 | Pages: 5458-5466

10.1182/bloodadvances.2024013743 | PMID 39213424 Get It

Abstract There are limited data assessing the risk scores for primary treatment failure (PTF) in patients with classical Hodgkin lymphoma (cHL; PTF-cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). ECLIPSE (Evaluation of Classical Hodgkin Lymphoma patients wIth Primary treatment failure and analySis of outcomEs) is a multicenter retrospective cohort of patients with PTF-cHL (aged ≥15 years) diagnosed on or after 1 January 2005, at 15 US medical centers. PTF was defined as 1 of the following patterns of failure: (1) progressive disease by imaging during or within 6 weeks of completion of frontline chemotherapy (primary progression [PP]); (2) partial response (PR) or stable disease (SD) by imaging after completion of frontline treatment (PR/SD); (3) progression of disease by imaging (and confirmed by biopsy) within 12 months of frontline therapy completion after prior documentation of complete response (CR; early relapse [ER]). A total of 478 patients were included in the analysis. Among these, 217 (45%) were PP, 86 (18%) were PR/SD, and 175 (37%) were ER. The 6-month and 1-year cumulative incidence of nonrelapse mortality after auto-HCT were 0.9% and 1.1%, respectively. The median progression-free survival (PFS) and overall survival (OS) after auto-HCT were 4.33 and 10.09 years, respectively. Although those not in CR at the time of auto-HCT were associated with inferior PFS and OS, advanced age and diagnosis before 2011 were associated with inferior OS. This study showcases the safety and long-term efficacy of auto-HCT, even in patients with high-risk disease who are traditionally considered chemotherapy refractory, and will serve as a benchmark for the ongoing transplant vs no transplant trials.
Technical Factors Associated With the Benefit of Prophylactic Pancreatic Stent Placement During High-Risk Endoscopic Retrograde Cholangiopancreatography: A Secondary Analysis of the SVI Trial Data Set
Elmunzer, B. Joseph , Zhang, Jingwen , Coté, Gregory A. , Wani, Sachin , Shah, Raj J. , Bang, Ji Young , Varadarajulu, Shyam , Singh, Vikesh K. , Khashab, Mouen A. , Kwon, Richard S. , Scheiman, James M., Keilin, Steven , Chak, Amitabh , Slivka, Adam, Mullady, Daniel , Kushnir, Vladimir , Buxbaum, James , Keswani, Rajesh N. , Gardner, Timothy B. , Forbes, Nauzer , Rastogi, Amit, Ross, Andrew S., Law, Joanna K. , Chen, Yen‐I , Smith, Zachary L. , Petersen, Bret T. , Wang, Andrew Y. , Saltzman, John R. , Spitzer, Rebecca L., Ordiah, Collins, Spino, Cathie , Foster, Lydia D. , Durkalski‐Mauldin, Valerie, Group*, on behalf of the SVI Study, Shah, Raj , Singh, Vikesh K , Kwon, Richard S , Willingham, Field F , Chak, Amitabh , Mullady, Daniel , Forbes, Nauzer , Ross, Andrew , Law, Joanna , Chen, Yen-I , Smith, Zachary L , Serrano, Jose , Petersen, Bret, Wang, Andrew Y , Saltzman, John R , Spino, Cathie , Foster, Lydia D , Edmundowicz, Steven A. , Willingham, Field F. , Papachristou, Georgios I. , Yachimski, Patrick , Barkun, Alan , Serrano, José , Group*, on behalf of the SVI Study

Mayo Clinic

American Journal of Gastroenterology | August 27, 2024 | Volume: 120 | Issue: 4 | Pages: 811-815

10.14309/ajg.0000000000003052 | PMID 39207308 Get It

INTRODUCTION: Prophylactic pancreatic stent placement (PSP) is effective for preventing pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk cases, but the optimal technical approach to this intervention remains uncertain. METHODS: In this secondary analysis of 787 clinical trial patients who underwent successful stent placement, we studied the impact of (i) whether pancreatic wire access was achieved for the sole purpose of PSP or naturally during the conduct of the case, (ii) the amount of effort expended on PSP, (iii) stent length, (iv) stent diameter, and (v) guidewire caliber. We used logistic regression models to examine the adjusted association between each technical factor and post-ERCP pancreatitis (PEP). RESULTS: Ninety-one of the 787 patients experienced PEP. There was no clear association between PEP and whether pancreatic wire access was achieved for the sole purpose of PSP (vs occurring naturally; odds ratio [OR] 0.82, 95% confidence interval [CI] 0.37–1.84), whether substantial effort expended on stent placement (vs nonsubstantial effort; OR 1.58, 95% CI 0.73–3.45), stent length (>5 vs ≤5 cm; OR 1.01, 95% CI 0.63–1.61), stent diameter (≥5 vs <5 Fr; OR 1.13, 95% CI 0.65–1.96), or guidewire caliber (0.035 vs 0.025 in; 0.83, 95% CI 0.49–1.41). DISCUSSION: The 5 modifiable technical factors studied in this secondary analysis of large-scale randomized trial data did not appear to have a strong impact on the benefit of prophylactic PSP in preventing PEP after high-risk ERCP. Within the limitations of post hoc subgroup analysis, these findings may have important implications in procedural decision making and suggest that the benefit of PSP is robust to variations in technical approach.
Representation of women in clinical trials supporting FDA ‐approval of contemporary cancer therapies
Kalathoor, Sujay , Ghazi, Sanam , Otieno, Beryl, Babcook, Melissa A., Chen, Sunnia T. , Nidhi, Neha, Bae, Junu, Pierre‐Charles, Jovan , Breathett, Khadijah , Mazimba, Sula , Mohammed, Selma F. , Carter, Rebecca R. , Ferdousi, Mussammat , Kola‐Kehinde, Onaopepo , McLaughlin, Eric , Brammer, Jonathan E. , Ruz, Patrick, Khan, Sarah , Odei, Bismarck , Patel, Prem, Addison, Daniel , Breathett, Khadijah , Nidhi, Neha, Johnson, Amber E , Brewer, LaPrincess C. , Bonsu, Janice M. , Mitchell, Darrion , Wei, Lai , Patel, Prem, Paskett, Electra D.

Mayo Clinic

International Journal of Cancer | August 19, 2024 | Volume: 155 | Issue: 11 | Pages: 1958-1968

10.1002/ijc.35110 | PMID 39155749 Get It

Abstract Contemporary anticancer therapies frequently have different efficacy and side effects in men and women. Yet, whether women are well‐represented in pivotal trials supporting contemporary anticancer drugs is unknown. Leveraging the Drugs@FDA database, clinicaltrials.gov , MEDLINE, and publicly available FDA‐drug‐reviews, we identified all pivotal (phase II and III) non‐sex specific trials supporting FDA‐approval of anticancer drugs (1998–2018). Observed‐enrollment‐rates were compared to expected‐population‐rates derived from concurrent US‐National‐Cancer‐Institute's Surveillance‐Epidemiology‐and‐End‐Results (SEER) reported rates and US‐Census databases. Primary outcome was the proportional representation of women across trials, evaluated by a participation‐to‐prevalence ratio (PPR), according to cancer type. Secondary outcome was the report of any sex‐specific analysis of efficacy and/or safety, irrespective of treatment‐arm. Overall, there were 148 trials, enrolling 60,216 participants (60.5 ± 4.0 years, 40.7% female, 79.1% biologic, targeted, or immune‐based therapies) evaluating 99 drugs. Sex was reported in 146 (98.6%) trials, wherein 40.7% (24,538) were women, compared to 59.3% (35,678) men ( p < .01). Altogether, women were under‐represented in 66.9% trials compared to the proportional incidence of cancers by respective disease type; weight‐average PPR of 0.91 (relative difference: ‐9.1%, p < .01). Women were most under‐represented in gastric (PPR = 0.63), liver (PPR = 0.71), and lung (PPR = .81) cancer trials. Sex‐based safety data was reported in 4.0% trials. There was no association between adequate female enrollment and drug efficacy (HR: 0.616 vs. 0.613, p = .96). Over time, there was no difference in the percentage of women recruited into clinical trials. Among pivotal clinical trials supporting contemporary FDA‐approved cancer drugs, women were frequently under‐represented and sex‐specific‐efficacy and safety‐outcomes were commonly not reported.
Potential roles for artificial intelligence in clinical microbiology from improved diagnostic accuracy to solving the staffing crisis
Soliman, Amr , Marouf, Mohamed , Pancholi, Preeti , Graf, Erin, Soliman, Amr , Marouf, Mohamed , Graf, Erin H. , Parwani, Anil Vasdev

Mayo Clinic

American Journal of Clinical Pathology | August 13, 2024 | Volume: 163 | Issue: 2 | Pages: 162-168

10.1093/ajcp/aqae107 | PMID 39136261 Get It

Abstract Objectives This review summarizes the current and potential uses of artificial intelligence (AI) in the current state of clinical microbiology with a focus on replacement of labor-intensive tasks. Methods A search was conducted on PubMed using the key terms clinical microbiology and artificial intelligence. Studies were reviewed for relevance to clinical microbiology, current diagnostic techniques, and potential advantages of AI in routine microbiology workflows. Results Numerous studies highlight potential labor, as well as diagnostic accuracy, benefits to the implementation of AI for slide-based and macroscopic digital image analyses. These range from Gram stain interpretation to categorization and quantitation of culture growth. Conclusions Artificial intelligence applications in clinical microbiology significantly enhance diagnostic accuracy and efficiency, offering promising solutions to labor-intensive tasks and staffing shortages. More research efforts and US Food and Drug Administration clearance are still required to fully incorporate these AI applications into routine clinical laboratory practices.